Another New Approach to Cytology

01 Feb 1999

The founder and former CEO of AccuMed International Inc., Peter Gombrich, has started a new company based on licensing and acquisitions in the fields of cytology and urology. He is using an innovative financing strategy that merges the privately held InPath LLC into Bell National Corp., a publically traded shell company. This allows Inpath to obtain cash and offer investors an exit, despite the coolness of public markets to small cap stocks.

The public markets have been cruel to small diagnostics companies, and that includes those involved in the once hot area of new cytology technologies. Witness the troubles of Neuromedical Systems Inc. and, more recently, AccuMed International Inc. , which got burned selling an automated imaging system for reviewing Pap smear slides to clinical laboratories reluctant to spend their limited budgets on unproven, expensive systems.

Now the founder and former CEO of AccuMed, Peter Gombrich, has started a new company based on licensing and acquisitions....